CD4 and herpes zoster: The adjuvanted recombinant zoster vaccine (RZV) is a novel zoster vaccine containing the VZV gE antigen, a primary target of CD4+ T-cell responses, and a liposome-based AS01B adjuvant (Figure 3) [137].